LLY ▲ +0.6% - Eli Lilly and Company
$LLY - Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
30-SEP-2026 10:15 AM ET
Share this post
More filings for $LLY
LLY ▲ +0.0% - Eli Lilly and CompanySep 29, 2026LLY ▼ -0.2% - Eli Lilly and CompanySep 29, 2026LLY ▼ -0.8% - Eli Lilly and CompanySep 29, 2026LLY ▼ -0.1% - Eli Lilly and CompanySep 29, 2026LLY ▲ +0.2% - Eli Lilly and CompanySep 29, 2026LLY ▲ +0.3% - Eli Lilly and CompanySep 29, 2026
View full $LLY filing history →💬 Comments
Loading comments…
Leave a comment
